Annual D&A
$24.40 M
+$12.65 M+107.57%
December 31, 2023
Summary
- As of February 12, 2025, RXRX annual depreciation & amortization is $24.40 million, with the most recent change of +$12.65 million (+107.57%) on December 31, 2023.
- During the last 3 years, RXRX annual D&A has risen by +$20.46 million (+518.87%).
- RXRX annual D&A is now at all-time high.
Performance
RXRX Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$7.20 M
-$1.77 M-19.74%
September 30, 2024
Summary
- As of February 12, 2025, RXRX quarterly depreciation & amortization is $7.20 million, with the most recent change of -$1.77 million (-19.74%) on September 30, 2024.
- Over the past year, RXRX quarterly D&A has dropped by -$179.00 thousand (-2.43%).
- RXRX quarterly D&A is now -19.74% below its all-time high of $8.97 million, reached on June 30, 2024.
Performance
RXRX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$31.10 M
-$380.00 K-1.21%
September 30, 2024
Summary
- As of February 12, 2025, RXRX TTM depreciation & amortization is $31.10 million, with the most recent change of -$380.00 thousand (-1.21%) on September 30, 2024.
- Over the past year, RXRX TTM D&A has increased by +$3.04 million (+10.86%).
- RXRX TTM D&A is now -1.21% below its all-time high of $31.48 million, reached on June 30, 2024.
Performance
RXRX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
RXRX Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +107.6% | -2.4% | +10.9% |
| 3 y3 years | +518.9% | +124.0% | +164.5% |
| 5 y5 years | +880.4% | +124.0% | +164.5% |
RXRX Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +190.3% | -19.7% | +221.9% | -1.2% | +270.0% |
| 5 y | 5-year | at high | +880.4% | -19.7% | +739.9% | -1.2% | +3218.7% |
| alltime | all time | at high | +880.4% | -19.7% | +739.9% | -1.2% | +3218.7% |
Recursion Pharmaceuticals Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $7.20 M(-19.7%) | $31.10 M(-1.2%) |
| Jun 2024 | - | $8.97 M(+21.6%) | $31.48 M(+12.2%) |
| Mar 2024 | - | $7.38 M(-2.3%) | $28.05 M(+15.0%) |
| Dec 2023 | $24.40 M(+107.6%) | $7.55 M(-0.3%) | $24.40 M(+21.6%) |
| Sep 2023 | - | $7.58 M(+36.7%) | $20.06 M(+29.7%) |
| Jun 2023 | - | $5.54 M(+48.7%) | $15.47 M(+21.7%) |
| Mar 2023 | - | $3.73 M(+16.0%) | $12.72 M(+8.2%) |
| Dec 2022 | $11.76 M | $3.21 M(+7.5%) | $11.76 M(+9.1%) |
| Sep 2022 | - | $2.99 M(+7.3%) | $10.78 M(+5.4%) |
| Jun 2022 | - | $2.79 M(+0.7%) | $10.22 M(+4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $2.77 M(+23.7%) | $9.77 M(+16.2%) |
| Dec 2021 | $8.40 M(+113.2%) | $2.24 M(-8.2%) | $8.40 M(+15.2%) |
| Sep 2021 | - | $2.44 M(+4.5%) | $7.29 M(+27.6%) |
| Jun 2021 | - | $2.33 M(+66.3%) | $5.71 M(+29.7%) |
| Mar 2021 | - | $1.40 M(+24.6%) | $4.41 M(+11.8%) |
| Dec 2020 | $3.94 M(+58.4%) | - | - |
| Dec 2020 | - | $1.13 M(+31.3%) | $3.94 M(+39.9%) |
| Sep 2020 | - | $857.00 K(-16.3%) | $2.82 M(+43.7%) |
| Jun 2020 | - | $1.02 M(+9.3%) | $1.96 M(+109.3%) |
| Mar 2020 | - | $937.00 K | $937.00 K |
| Dec 2019 | $2.49 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual depreciation & amortization?
- What is the all time high annual D&A for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual D&A year-on-year change?
- What is Recursion Pharmaceuticals quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly D&A year-on-year change?
- What is Recursion Pharmaceuticals TTM depreciation & amortization?
- What is the all time high TTM D&A for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM D&A year-on-year change?
What is Recursion Pharmaceuticals annual depreciation & amortization?
The current annual D&A of RXRX is $24.40 M
What is the all time high annual D&A for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual depreciation & amortization is $24.40 M
What is Recursion Pharmaceuticals annual D&A year-on-year change?
Over the past year, RXRX annual depreciation & amortization has changed by +$12.65 M (+107.57%)
What is Recursion Pharmaceuticals quarterly depreciation & amortization?
The current quarterly D&A of RXRX is $7.20 M
What is the all time high quarterly D&A for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly depreciation & amortization is $8.97 M
What is Recursion Pharmaceuticals quarterly D&A year-on-year change?
Over the past year, RXRX quarterly depreciation & amortization has changed by -$179.00 K (-2.43%)
What is Recursion Pharmaceuticals TTM depreciation & amortization?
The current TTM D&A of RXRX is $31.10 M
What is the all time high TTM D&A for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM depreciation & amortization is $31.48 M
What is Recursion Pharmaceuticals TTM D&A year-on-year change?
Over the past year, RXRX TTM depreciation & amortization has changed by +$3.04 M (+10.86%)